Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 2 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 3 | 4 |
| 2016 | 4 | 3 | 7 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
| 2025 | 2 | 0 | 2 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma. Neuro Oncol. 2026 Oct 01; 28(10):2485-2499.
-
Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors. Signal Transduct Target Ther. 2026 Jun 05; 11(1).
-
Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant. Pediatr Blood Cancer. 2026 Jun; 73(6):e70259.
-
Histone acetylation modulators in breast cancer. Breast Cancer Res. 2025 03 31; 27(1):49.
-
Hunting potential SIRT2 inhibitors towards cancer treatment: Drug repurposing, molecular dynamics, and binding energy computations. Biochem Biophys Res Commun. 2025 05 26; 760:151701.
-
Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. Commun Biol. 2024 10 04; 7(1):1257.
-
Critical Role of histone deacetylase 3 in the regulation of kidney inflammation and fibrosis. Kidney Int. 2024 04; 105(4):775-790.
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 04; 80(4):610-621.
-
ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat. Eur J Cell Biol. 2023 Sep; 102(3):151341.
-
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. Neuro Oncol. 2022 04 01; 24(4):655-664.